Risk–benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study
Journal of the European Academy of Dermatology and Venereology
Volume
37
Issue
5
Start Page
e572
End Page
e575
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the European Academy of Dermatology and Venereology Vol.37 No.5 (2023) , e572-e575
Suggested Citation
Seree-aphinan C., Suchonwanit P., Rattanakaemakorn P., Pomsoong C., Ratanapokasatit Y., Setthaudom C., Suangtamai T., Chanprapaph K. Risk–benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study. Journal of the European Academy of Dermatology and Venereology Vol.37 No.5 (2023) , e572-e575. e575. doi:10.1111/jdv.18890 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82060
Title
Risk–benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study
